Insider · CIK 0001774518
Phaedra Chrousos
Files at VNDA (Vanda Pharmaceuticals Inc.). First filing -, latest -.
In brief
Phaedra Chrousos files SEC Form 4 as director at VNDA (Vanda Pharmaceuticals Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Phaedra Chrousos has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | VNDA Vanda Pharmaceuticals Inc. | AGrant or award Common Stock | +41,600 | $0.00 | $0 | 164,950 | Jun 8, 2026 |
| Jun 5, 2025 | VNDA Vanda Pharmaceuticals Inc. | AGrant or award Common Stock | +59,225 | $0.00 | $0 | 123,350 | Jun 9, 2025 |
Questions about Phaedra Chrousos
Answered from the filings on this page, as of the latest one.
Is Phaedra Chrousos buying or selling?
Phaedra Chrousos has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Phaedra Chrousos's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Phaedra Chrousos has 0.
Where does Phaedra Chrousos file Form 4?
Phaedra Chrousos has filed Form 4 at VNDA (Vanda Pharmaceuticals Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.